In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 11 to 20 of 294

TitleTypeExpected publication date
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]Technology appraisal guidance
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]Technology appraisal guidance
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Technology appraisal guidanceTBC
Asunercept for treating glioblastoma [ID1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]Technology appraisal guidanceTBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]Technology appraisal guidanceTBC
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All